Key insights
- China SXT Pharmaceuticals (SXTC) implements a dual-class share structure after a 99.65% stock decline over the past year. The restructuring, granting Class B shares 50 votes each, aims to provide stability. However, given the company's small market cap ($1.31M) and continued price declines, the impact on broader US equities is expected to be slightly negative, primarily reflecting increased risk perception associated with certain Chinese ADRs.
TAIZHOU, China - China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) announced its Class A Ordinary Shares will begin trading on The Nasdaq Stock Market under the symbol SXTC starting Tuesday, according to a press release statement.
The company, which manufactures and sells Traditional Chinese Medicine Pieces, implemented a dual-class share structure following shareholder approval at a special meeting held on July 28, 2025. The restructuring comes as the stock has declined 99.65% over the past year, with shares dropping 21% in the last week alone. The company currently holds a market capitalization of just $1.31 million. Shareholders approved changes to the company’s authorized share capital to create two classes of shares.
The new structure consists of Class A Ordinary Shares and Class B Ordinary Shares. Class B Ordinary Shares carry 50 votes per share on shareholder resolutions, while the company’s existing ordinary shares were designated as Class A Ordinary Shares. Both classes have no par value.
The share reclassification became effective after the company filed its Amended and Restated Memorandum and Articles of Association with the Companies Registry of the British Virgin Islands. The company is authorized to issue an unlimited number of shares across both classes.
Shareholders holding shares through banks, brokers, or other nominees will have their shares automatically adjusted to reflect the reclassification. Questions can be directed to brokers or the company’s transfer agent, Transhare Corporation, at +1 303-662-1122.
Founded in 2005, China SXT Pharmaceuticals is headquartered in Taizhou City, Jiangsu Province, China. The company focuses on research, development, manufacturing, marketing, and sales of traditional Chinese medicine pieces and related products. Despite recent price declines, InvestingPro analysis suggests the stock may be undervalued, with shares trading at a Price/Book ratio of just 0.06. Investors can access comprehensive Fair Value analysis and 18 additional ProTips on the most undervalued stocks list.
In other recent news, China SXT Pharmaceuticals announced a 1-for-150 share consolidation, effective February 3, 2026, which will reduce the number of outstanding Class A ordinary shares from approximately 143.7 million to about 958,000. The company also raised $10 million through a registered direct offering, selling 66,666,666 Class A ordinary shares to a single investor at $0.15 per share. This transaction included pre-funded warrants with an exercise price of $0.001 per share. Additionally, China SXT Pharmaceuticals launched a Strategic Artificial Intelligence Insights Initiative aimed at integrating AI-driven analytics into its product portfolio planning and market intelligence processes. These developments reflect the company’s ongoing strategic moves to enhance its operations and financial standing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.